Want smarter insights in your inbox? Sign up for our weekly newsletters to get only what matters to enterprise AI, data, and security leaders. Subscribe Now
Pacific Biosciences, formerly known as Nanofluidics, a Menlo Park, Calif. company focused on medications resulting from DNA gene sequencing, has raised around $50 million in a forth round of funding.
Investors include Maverick Capital, and return backers Alloy Ventures, Kleiner Perkins Caufield & Byers and Mohr, Davidow Ventures, according to PE Week, which first reported the funding today. Pacific Biosciences previously has raised more than $15M.
Here is an article about its technology (free after registration).
(This story first posted 1/12)